Skip to main content

New medicines advice for NHS Wales

Welsh Government has approved advice from the All Wales Medicines Strategy Group (AWMSG) for five medicines.

  • Nitisinone (Orfadin®) is recommended for the treatment of a rare disease called alkaptonuria (AKU) in adults.
  • Everolimus (Votubia®) dispersible tablets are recommended to treat children aged 2 years and above and adults with partial seizures with or without secondary generalisation (epilepsy) associated with a genetic disorder called tuberous sclerosis complex (TSC) and which are not controlled by other antiepileptic medicines. Votubia® is given together with other medicines for epilepsy.
  • Amikacin liposomal (Arikayce®) is recommended for use by inhalation to treat lung infection caused by Mycobacterium avium Complex in adults with limited treatment options who do not have cystic fibrosis. Amikacin belongs to a group of antibiotics called aminoglycosides which stop the growth of certain bacteria that cause infections.
  • Dolutegravir (Tivicay®) dispersible tablets are recommended to treat HIV (human immunodeficiency virus) infection in adults, adolescents and children of at least 4 weeks of age or older, and who weigh at least 3 kg. Tivicay® is always used in combination with other antiretroviral medicines.
  • Etravirine (Intelence®) is recommended as an option for use in combination with other anti-HIV medicines to treat adults and children 2 years of age and older who are infected by HIV and who have used other anti-HIV medicines before.

AWTTC’s Patient Access to Medicines Service (PAMS) supports the AWMSG to assess and monitor new medicines in Wales.